论文部分内容阅读
8月5日,国家工信部节能与综合利用司环境保护处毕俊生处长在市经信委董德义副主任、傅绍春、宋涛处长等陪同下,对海利尔药业集团清洁生产示范情况进行了调研。海利尔药业集团以国家863科技成果为基础,正在实施“吡虫啉原药清洁生产新工艺及废水综合治理新技术应用示范”项目。该项目在国内首次采用具有自主知识产权的吡虫啉原药生产的缩合、二氯环合和废水综合治理等新技术对原有生产工艺进行清洁生产改造,用氯化环合试剂替代三氯氧磷,减少了N,N-二甲基甲酰胺用量,从源头减少生产吡虫啉产生的COD和废水量。
On August 5, Mr. Bi Junsheng, director of the Environmental Protection Department of the Energy Conservation and Comprehensive Utilization Department of the Ministry of Industry and Information Technology, accompanied by Dong Deyi, deputy director of the City Economic Commission, Fu Shaochun and Director Song Tao, conducted a demonstration on the clean production demonstration of Heilier Pharmaceutical Group Research. Heilier Pharmaceutical Group based on the achievements of 863 national science and technology, is implementing the “new technology of imidacloprid cleaner production and comprehensive utilization of wastewater treatment technology demonstration” project. The project in the country for the first time with the independent intellectual property rights of the original production of imidacloprid condensation, dichlorohepta and wastewater treatment and other new technologies on the original production process of cleaner production transformation, with chlorinated reagents to replace phosphorus oxychloride , Reducing the amount of N, N-dimethylformamide, from the source to reduce the production of imidacloprid COD and waste water.